Atropine and Pralidoxime Chloride, 'Duodote Kit"
ID: CombinedDuoType: Combined Synopsis/Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF THE ASSISTANT SECRETARY FOR ADMINISTRATION (ASA)PROGRAM SUPPORT CENTER ACQ MGMT SVCROCKVILLE, MD, 20857, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Set Aside

No Set aside used (NONE)

Original Source

https://sam.gov/workspace/contract/opp/623b1c3d7b604a29b7bbccb16091d878/view
Timeline
    Description

    The Department of Health and Human Services, specifically the Office of the Assistant Secretary for Administration, is seeking quotes for the procurement of Atropine and Pralidoxime Chloride Autoinjectors, known as the "Duodote Kit." The requirement includes a total of 171 boxes, each containing 30 autoinjectors, to be delivered to the DHHS Receiving Dock located in Perry Point, Maryland. These autoinjectors are critical for emergency medical treatment, particularly in cases of organophosphate poisoning. Interested vendors should direct their inquiries to Tim Bouchelle at Timothy.Bouchelle@hhs.gov or by phone at 443-947-6039, with no set-aside restrictions applicable to this solicitation.

    Point(s) of Contact
    Tim Bouchelle
    (443) 947-6039
    (410) 642-3566
    Timothy.Bouchelle@hhs.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Atropine and Pralidoxime Chloride, 'Duodote Kit"
    Currently viewing
    Combined Synopsis/Solicitation
    Similar Opportunities
    65--PYRIDOSTIGMINE BROM
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is seeking quotes for the procurement of Pyridostigmine Bromide, specifically NSN 6505-01-725-2767, under a total small business set-aside. The requirement includes a quantity of 1,000 units to be delivered to the W05J Medical Maintenance Operations Division at Tobyhanna within 20 days after the order is placed. Pyridostigmine Bromide is a critical medication used to treat certain conditions, making this procurement essential for military medical operations. Interested vendors must submit their quotes electronically, and any inquiries should be directed to the buyer via email at DibbsBSM@dla.mil, as hard copies of the solicitation will not be provided.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense (DoD) is soliciting quotes for pharmaceutical agents as part of its Uniform Formulary Blanket Purchase Agreement (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) through the Defense Health Agency (DHA). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of drugs to determine their classification within the formulary. The P&T Committee will review newly approved drugs, including agents for pulmonary, gynecological, endocrine, atopy, skeletal muscle relaxants, and pain management, with quotes due by December 9, 2025, ahead of the committee meeting scheduled for February 4-5, 2026. Interested manufacturers should contact Stephanie Erpelding or Tracy Banks for further details and ensure compliance with submission requirements outlined in the RFQ HT9402-26-Q-9102.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense (DoD) is seeking quotations for pharmaceutical agents as part of the Pharmacy Uniform Formulary Blanket Purchase Agreement (UF BPA) and the Uniform Formulary Additional Discount Program (UF ADP) to support the Military Health System (MHS). This procurement aims to establish an effective pharmacy benefits program by evaluating the clinical and cost-effectiveness of various pharmaceutical agents, including oncological and antihemophilic agents, for inclusion in the DoD Uniform Formulary. Interested manufacturers must submit their quotes by January 16, 2026, with a pre-quotation teleconference scheduled for November 20, 2025. For further inquiries, contact Tracy Banks at tracy.e.banks2.civ@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil.
    Reactive and Inactive Skin Decontamination Lotion
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is seeking procurement for Reactive and Inactive Skin Decontamination Lotion (RSDL/ISDL). This contract involves the acquisition of specialized drugs and biologicals designed for decontaminating skin exposed to hazardous substances, which is critical for the safety and protection of military personnel in various operational environments. The opportunity is detailed in a redacted Justification and Approval document, indicating the importance of these products in maintaining troop readiness and safety. Interested vendors can reach out to Myrna I. Rodriguez at Myrna.Rodriguez@dla.mil or call 215.737.4711 for further information regarding this procurement.
    Ondansetron Orally Disintegrating Tablets
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.
    Detector Kit, Chemical
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Land Warren, is soliciting offers for a firm-fixed price contract for 22 Chemical Detector Kits (NSN: 6665-01-706-8739, Manufacturer Part Number: 6001-000082-2), with an option for an additional 22 units. This procurement is critical for ensuring the availability of reliable hazard-detecting instruments, which play a vital role in military operations and safety protocols. Proposals must be submitted via email to Patricia Roussin at patricia.roussin@dla.mil by December 15, 2025, at 11:59 PM EST, and interested parties should note that a Technical Data Package is available on sam.gov, requiring a current DD 2345 for access. Compliance with specific packaging, marking, and delivery requirements is essential, with deliveries to be made FOB Destination to Pine Bluff, AR, within 90 days after contract award.
    65--REFILL,INDIVIDUAL F
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is seeking quotes for the procurement of individual refill units, specifically NSN 6545016638243. The requirement includes a quantity of 25 units to be delivered to the 0189 CS BN CO A Composite within 20 days after order (ADO), with the approved source being 515E6 81-303-30. These medical supplies are crucial for military operations, ensuring that personnel have access to necessary medical equipment. Interested vendors must submit their quotes electronically, as hard copies will not be available, and any inquiries should be directed to the buyer via email at DibbsBSM@dla.mil.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    J&A Procurement of Smallpox (Mpox) Vaccine for the Strategic National Stockpile
    Buyer not available
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking to procure additional doses of the JYNNEOS™ vaccine for the Strategic National Stockpile in response to the ongoing monkeypox outbreak. The procurement aims to rapidly secure 11 million doses of the vaccine by utilizing existing bulk drug substance and to enhance manufacturing capacity through technology transfer to contract manufacturing organizations. The JYNNEOS™ vaccine is critical as it is the only licensed vaccine for both smallpox and monkeypox, making it essential for public health preparedness. Interested parties can contact Yifan Yang at yifan.yang@hhs.gov, with the total estimated value of the contract modification being $992,400,000.
    COVID 19 Tests
    Buyer not available
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response, is seeking procurement for COVID-19 tests. The opportunity involves the acquisition of in vitro diagnostic substances, reagents, test kits, and sets, with a focus on ensuring compliance with the Trade Agreements Act (TAA). This procurement is critical for enhancing the nation's testing capabilities in response to the ongoing pandemic. Interested vendors can reach out to Junli Collins at junli.collins@hhs.gov or Judy Williams at judy.williams2@hhs.gov for further details, as outlined in the attached justification document.